A phase II clinical trial (NCT04189445) demonstrated tumor shrinkage in 58% of patients with FGFR2-amplified gastric cancer, but the objective response rate (ORR) varied between 17,9% and 26%. The gene discussed is FGFR2; the disease is gastric cancer.